株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ライフスタイルOTC:動向、開発、機会および戦略

Lifestyle OTCs: Trends, Developments, Opportunities and Strategies

発行 Nicholas Hall & Company 商品コード 314924
出版日 ページ情報 英文
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Nicholas Hall & Company社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
ライフスタイルOTC:動向、開発、機会および戦略 Lifestyle OTCs: Trends, Developments, Opportunities and Strategies
出版日: 2014年12月04日 ページ情報: 英文
概要

当レポートは、肥満治療、喫煙規制、鎮痛剤&睡眠補助薬、性の健康、アイケア、家庭用診断、全身性心血管疾患およびコレステロール低下など様々なカテゴリーをカバーするライフスタイルOTCについて調査し、アイケア売上を促進する主な動向、スタチンOTC薬:Zocorの失敗後、非RX(非処方薬)に将来はあるのか、米国におけるLipitorの切り替えは新しいOTCカテゴリーを生み出せるのか、睡眠補助薬におけるZzzQuilの華々しい台頭からの教訓、またe-シガレットの増加は従来のOTC喫煙規制製品にとって何を意味するかといった問題の分析をまとめ、お届けいたします。

エグゼクティブサマリー

アイケア

  • 概要
  • 米国
    • 人工涙液
    • 眼科用充血除去剤
    • コンタクトレンズケア
    • 展望
  • カナダ
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • ポーランド
  • 中国
  • 日本
  • オーストラリア
  • インド
  • 韓国
  • ブラジル
  • メキシコ
  • ベネズエラ
  • アイケアの展望

心臓の健康

  • 概要
  • 全身性心血管疾患
  • コレステロール低下
  • サプリメント
  • 心臓の健康の展望

家庭用診断

  • 概要
  • 血糖メーター
  • 血圧モニター
  • 家族計画
  • 尿検査
  • フィットネス・睡眠モニター

鎮痛剤&睡眠補助薬

  • 概要
  • 米国
  • カナダ
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • ロシア
  • ポーランド
  • 中国
  • 日本
  • オーストラリア
  • ブラジル
  • メキシコ
  • 鎮痛剤&睡眠補助薬の展望

性の健康

  • 概要
  • 避妊
  • 勃起障害(ED)
  • クラミジア治療

喫煙規制

  • 概要
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • Rx喫煙規制
  • OTC喫煙規制の展望

泌尿器用医薬品

  • 概要
  • UTI
  • 良性前立腺過形成(BPH)
  • 化活動膀胱(OAB)
  • 泌尿器用医薬品の展望

減量

  • 概要
  • 規制
  • 主な世界の発展
  • 米国の減量市場
  • リパーゼ阻害剤

MライフスタイルOTC薬の展望

  • 世界のライフスタイルOTC薬展望
  • カテゴリー別の展望
目次

Author: Nicholas Hall Reports

Publishing at the end of November is our new category report: Lifestyle OTCs. It will provide a comprehensive review of a vital part of the OTC industry covering such diverse categories as obesity treatments, smoking control, sedatives & sleep aids, sexual health, eye care, home diagnostics, systemic cardiovasculars and cholesterol reduction.

The report will help to answer a series of question including:

  • What are the key trends that will drive eye care sales?
  • Is there still a non-Rx future for statins after the failure of OTC Zocor? Can Lipitor switch in the US and create a successful new OTC category?
  • What can be learned from the meteoric rise of ZzzQuil among sleep aids?
  • What does the rise of e-cigarettes mean for traditional OTC smoking control products?

Chapters:

  • Executive Summary
  • Eye Care
  • Heart Health
  • Home Diagnostics
  • Sedatives & Sleep Aids
  • Sexual Health
  • Smoking Control
  • Urinary Products
  • Weight Loss
  • Lifestyle OTCs Outlook

Whether you already have a vested interest in this sector of the OTC market or are curious to find out the trends & opportunities and learn from existing strategies, Lifestyle OTCs will have something for you.

Table of Contents

Executive summary

Eye care

  • Overview
    • Does the rise of a handful of big-name eye health players foreshadow a consolidation of the category
    • Brands for older consumer - a largely unfulfilled niche?
  • USA
    • Artificial tears
    • Eye decongestants
    • Contact lens care
    • Looking ahead
  • Canada
    • Artificial tears
    • Eye decongestants
    • Contact lens care
  • France
    • Artificial tears
    • Eye decongestants
    • Eye washes
    • Blepharitis treatments
    • Homeopathics
  • Germany
    • Artificial tears
    • Eye decongestants
  • Italy
    • Eye decongestants
    • Other eye care segments
  • UK
    • Brand case study: Optrex
    • Other eye care brands
  • Spain
    • Pure OTC brands expand as semi-ethicals decline
  • Russia
    • Strongest growth driven by high adspend
    • Lower tier brands enjoy a wide range of positionings
  • Poland
    • Starazolin's meteroic rise to eye care No.1 a result of diversification and focused A+P
    • International brands compete for share in a fragmented lower tier
  • China
    • Strong performances across the category drive a healthy topline
  • Japan
    • New ingredient launches diversify allergy eye care market
    • Dynamism of longline Rohto range drives topline growth
    • NPD key to growth in the fragmented lower tier
  • Australia
    • Established brands drive topline growth
    • Lower tier sees significant NPD investment
  • India
  • South Korea
  • Brazil
  • Mexico
  • Venezuela
  • Outlook for eye care

Heart health

  • Overview
  • Systemic cardiovasculars
    • Will aspirin gain expanded indications?
    • C&E Europe
    • Western Europe
    • North America
    • Asia-Pacific
    • Latin America
  • Cholesterol reduction
    • Number of people taking Rx statins for cholesterol reduction is increasing at a fast pace
    • What is the potential for an OTC cholesterol reduction category based on statins?
    • Zocor Heart Pro - a switch failure in the UK
    • Lipitor to switch in the US?
  • Supplements for health health
    • Omega-3 for heart health boosted by positive studies...
    • ...However, doubts are raised over their benefits
    • Blockbuster Rx omega-3 supplement Lovaza has global
    • OTC potential
    • Krill oil-based omega-3 supplement MegaRed makes waves
    • Important omega-3 launch in Japan
    • Co-enzyme Q10 reputation grows thanks to studies
    • Do phytosterol supplements for cholesterol reduction have a future?
  • Outlook for heart health

Home diagnostics

  • Overview
  • Blood glucose meters
    • North America
    • Europe
    • Prospects for blood glucose meters
  • Blood pressure monitors
    • North America
  • Family planning
    • Ovulation tests
      • North America
      • Europe
      • Alternative ovulation tests
    • Fertility tests
    • Pregnancy tests
      • Innovation and technological advances in pregnancy tests
      • North America
      • Europe
    • STD tests
    • A lack of OTC options
    • Taking the shame out of STD testing
  • Urine tests
  • Fitness & sleep monitors

Sedatives & sleep aids

  • Overview
    • What are the chances of Rx insomnia treatments switching OTC?
  • USA
    • Rx insomnia segment offers potential switches
    • Brand case study: ZzzQuil
    • Natural sleep aids a significant segment
    • Nasal strips losing out to liquid brands and natural options
  • Canada
    • Nasal strip Breathe Right dominates the category
    • Competitive diphenhydramine segment invigorated by ZzzQuil
    • Naturals segment faces competition from longline VMS ranges
  • Germany
    • Baldriparan faces growing competition from dynamic Neurexan
  • France
    • Natural sleep aids are growing well, but could not offset continued decline of sedatives
  • Italy
    • Valdispert and Pineal take largest share of fragmented category
  • Spain
    • Dormidina secures its position at the head of a sluggish category
  • UK
  • Russia
    • Dynamism of Afobazol a key contributor to overall growth
  • Poland
  • China
    • Allopathic segment underdeveloped, with Rx options a barrier
    • TCMs continue to grow to challenge Nao Bai Jin
  • Japan
    • Despite efforts to improve consumer awareness, sales of leading brands remain low
  • Australia
    • Longline naturals ranges account for majority of sales
    • Marketers of medicated brands using alternative methods to promote non-advertisable OTCs
    • Wide range of medical devices compete within small anti-snoring segment
  • Brazil
    • Passiflora brands dominant in a generally dynamic category
    • Brand case study: Seakalm
  • Mexico
  • Outlook for sedatives & sleep aids

Sexual health

  • Overview
  • Contraception
    • Emergency hormonal contraception
      • Asia-Pacific
      • North America
      • Western Europe
      • EHC in other key markets
      • Prospects for EHC
    • Daily oral contraception
      • Asian markets provide bulk of (limited) OTC daily OC sales
      • Pilot schemes increase availability of DOC in the UK
      • Calls in the US to switch DOC
      • Prospects for daily Ocs
  • Erectile dysfunction
    • The OTC potential of ED
    • New Zealand makes "first in world" switch of sildenafil
    • Viagra's eventual switch seen by many as inevitable
    • Developments among the main ED brands
    • Sanofi and Eli Lilly plan Cialis OTC launch for 2018
    • Pharmacy availability of ED without a prescription in the UK
    • China's ED market sees generic Viagra launch
    • Marketing for ED skews towards humour ... and a younger demographic
    • Prospects for ED treatments
  • Chlamydia treatments
    • UK alone in offering OTC chlamydia treatment

Smoking control

  • Overview
  • North America
    • USA
    • Canada
  • Europe
    • UK
    • France
    • Nordic markets
    • Germany
    • Spain
    • Poland
    • Russia
  • Asia-Pacific
    • Australia
    • Japan
    • China
    • India
    • South Korea
  • Latin America
  • Rx smoking control
  • E-cigarettes
    • Overview
    • Impact on current smoking control market
    • Regulation of e-cigarettes
    • Future of e-cigarettes
  • Prospects for OTC smoking control

Urinary products

  • Overview
  • UTIs
    • Cystitis treatments on the up in Europe
    • Outside Europe, US is the key market for UTI treatments
    • Does switch of antibiotics for UTIs in New Zealand herald new era for OTC treatment?
  • Benign prostatic hyperplasia
    • OTC treatments for BPH currently limited
    • What impact has Flomax Relief's switch in the UK made?
  • Overactive bladder
  • Outlook for urinary products

Weight loss

  • Overview
  • Regulatory roundup
  • Key global developments
  • US weight loss market
    • US regulators working to ensure safety and reliability
    • Meal replacements and diet plans a significant segment of dietary aids
    • MLM a growing presence in the US dietary supplements category
    • Weight loss supplements
  • Lipase inhibitors
    • Xenical is present across certain Asian markets
    • Alli's strong launch gives way to disappointing sales period, but recovery is on the cards
    • Alli launch process a textbook example of advisory OTC launch
    • Marketing strategy emphasises Alli's USP

Lifestyle OTCs outlook

  • Global prospects for lifestyle OTCs
  • Category prospects
Back to Top